Back to Authors

Schumacher, K R

0000-0001-8659-736X

Mayo Clinic

Division of Pediatric Cardiology, C.S. Mott Children's Hospital - University of Michigan, Ann Arbor, Michigan, USA.

Citations 2

Changes in nutritional status and the development of obesity and metabolic syndrome following pediatric heart transplantation
Sill, Jordan , Lukich, S., Alejos, A., Lim, H. , Chau, P., Lowery, Ray , McCormick, Amanda D. , Peng, David M. , Yu, Stella X. , Schumacher, Kurt R. , Lim, Heang M. , Sill, J , McCormick, A , Peng, D M , Schumacher, K R , Yu, S.

Pediatric Transplantation | May 20, 2024 | Volume: 28 | Issue: 4 | Pages: No page available

10.1111/petr.14782 Get It

AbstractBackgroundNutritional status in pediatric patients undergoing heart transplantation (HT) is frequently a focus of clinical management and requires high resource utilization. Pre‐operative nutrition status has been shown to affect post‐operative mortality but no studies have been performed to assess how nutritional status may change and the risk of developing nutritional comorbidities long‐term in the post‐transplant period.MethodsA single‐center retrospective chart review of patients ≥2 years of age who underwent heart transplantation between 1/1/2005 and 4/30/2020 was performed. Patient data were collected at listing, time of transplant, 1‐year, and 3‐year follow‐up post‐transplant. Nutrition status was classified based on body mass index (BMI) percentile in the primary analysis. Alternative nutritional indices, namely the nutrition risk index (NRI), prognostic nutrition index (PNI), and BMI z‐score, were utilized in secondary analyses.ResultsOf the 63 patients included, the proportion of patients with overweight/obese status increased from 21% at listing to 41% at 3‐year follow‐up. No underweight patients at listing became overweight/obese at follow‐up. Of patients who were overweight/obese at listing, 88% maintained that status at 3‐year follow‐up. Overweight/obese status at listing, 1‐year, and 3‐year post‐transplantation were significantly associated with developing metabolic syndrome. In comparison to the alternative nutritional indices, BMI percentile best predicted post‐transplant metabolic syndrome.ConclusionsThe results suggest that pediatric patients who undergo heart transplantation are at risk of developing overweight/obesity and related nutritional sequelae (ie, metabolic syndrome). Improved surveillance and interventions targeted toward overweight/obese HT patients should be investigated to reduce the burden of associated comorbidities.
Protein‐losing enteropathy recurrence after pediatric heart transplantation: Multicenter case series
Sagray, Ezequiel , Johnson, Jonathan N. , Schumacher, Kurt R. , West, Shawn C. , Lowery, Ray , Simpson, Kathleen E. , West, Shawn , Simpson, Kathleen , Schumacher, K R

Pediatric Transplantation | April 22, 2022 | Volume: 26 | Issue: 5 | Pages: No page available

10.1111/petr.14295 Get It

AbstractBackgroundProtein‐losing enteropathy (PLE) is a devastating complication of the Fontan circulation. Although orthotopic heart transplantation (HTx) typically results in resolution of PLE symptoms, isolated cases of PLE relapse have been described after HTx.MethodsPatients with Fontan‐related PLE who had undergone HTx at participating centers and experienced relapse of PLE during follow‐up were retrospectively identified. Available data related to pre‐ and post‐HTx characteristics and PLE events were collected.ResultsEight patients from four different centers were identified. Median time from Fontan procedure to the development of PLE was 8 years, and median age at HTx was 17 years (range 7.7–21). In all patients, PLE resolved at a median time of 1 month after HTx (0.3–5). PLE recurrences occurred at a median time of 7.5 months after HTx (2–132). Each occurrence was associated with one or more significant clinical events; most commonly cellular‐ or antibody‐mediated rejection; and less commonly graft dysfunction, infection, thrombosis, and posttransplant lymphoproliferative disease. PLE recurrences resolved after the successful treatment of the concomitant event, after a median time of 2 months in seven cases, while persisted and recurred in one patient in association with atypical mycobacterium infection and subsequent PTLD onset and relapses. Six patients were alive during follow‐up at a median time of 4 years (1.3–22.5) after HTx.ConclusionsThis is the largest series of PLE recurrence after HTx. All cases were associated with one or more concomitant and significant clinical events. PLE typically resolved after resolution of the inciting clinical event.